Company intelligence / Profile preview

江苏谦仁生物科技

Taizhou, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

Jiangsu Qianren Biotechnology is a biopharmaceutical company specializing in the research and development of mRNA-based vaccines and therapeutics. Headquartered in Taizhou's China Medical City, the company utilizes a proprietary mRNA platform and lipid nanoparticle (LNP) delivery technology to create innovative treatments for infectious diseases and oncology. Their lead programs focus on next-generation mRNA vaccines designed to provide robust immune responses with improved safety profiles. Qianren Bio is committed to building a comprehensive industrial chain that spans from molecular design and optimization to clinical development and commercial-scale manufacturing.

Therapeutic areas: Infectious Diseases
Modalities: mRNA-based drugsVaccineBiologic
Industry: Biotech

Beyond the preview

Go deeper on 江苏谦仁生物科技.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 江苏谦仁生物科技.

Explore the full profile